First of all, I want to point out that I recently came across the patent on their vehicle, which notes that it prevents CB from going systemic, and they have also figured out the stability problem:
From https://www.google.com/patents/EP3108879A1
Now the July news.
http://www.cassiopea.com/news-and-media/press-releases/yr-2017/hy2017.aspx
And full presentation: http://www.cassiopea.com/~/media/Files/C/Cassiopea/presentations/1H2017 public presentation/1H2017 public presentation.pdf
Which states that it won't come to market until 2021. f***. No data till Q4 2018 too.
Winlevi phase III is over in H1 2018 with launch in 2019.. Looks like a race between Winlevi (off label use for alopecia) and Polichem (topical finasteride with 50% less systemic exposure) to see if we can finally find an AA that doesn't rip our dicks off. But it sucks the trial of Breezula is in Germany and it sucks it will take so long.
From https://www.google.com/patents/EP3108879A1
In particular, these pharmacokinetic profiles show that the formulations described herein advantageously maximize topical delivery of cortexolone-17α-propionate in the skin and/or in the scalp while simultaneously minimizing systemic exposure to cortexolone-17α-propionate or any of its metabolites. Moreover, it has also been discovered that the pharmaceutical formulations described herein possess favorable stability profiles, allowing for finished product storage at room temperature for at least two years.
Now the July news.
http://www.cassiopea.com/news-and-media/press-releases/yr-2017/hy2017.aspx
We expect to recruit the last patient in the Winlevi® phase III clinical trial for acne in H2 2017 and then have the data report in H1 2018. By that time, we should be having the interim analysis report for the Breezula® phase II dose ranging trial which should then give us a solid basis for the planning of the next steps of the Company. Though we have had some slight delays in the clinical trials because we have increased our supervision effort in the enrollment process, I am pleased with our progress towards creating four valuable innovative products in the dermatology market and I am convinced that we continue to be on track to establish ourselves as a key player in the dermatology field
And full presentation: http://www.cassiopea.com/~/media/Files/C/Cassiopea/presentations/1H2017 public presentation/1H2017 public presentation.pdf
Which states that it won't come to market until 2021. f***. No data till Q4 2018 too.
Winlevi phase III is over in H1 2018 with launch in 2019.. Looks like a race between Winlevi (off label use for alopecia) and Polichem (topical finasteride with 50% less systemic exposure) to see if we can finally find an AA that doesn't rip our dicks off. But it sucks the trial of Breezula is in Germany and it sucks it will take so long.
Last edited: